GIST pipeline
What is next, and who is running it?
The next dated milestone on each program. A hollow marker is a registry primary completion date, not a company readout.
A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.
ClassNone selected
Phase 1 included.
Clear filters17 of 17 programs on this timeline
202520262027202820292030Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Today
anti-PD-L1 (with imatinib) 1
Atezolizumab + ImatinibPhase 2
Registry, Oct 2027
anti-PD-L1 (with regorafenib) 1
Envafolimab + RegorafenibPhase 2
Registry, Jul 30, 2027
Class not reported 1
DCC-3009Phase 1/2
Registry, May 2028
HIF-2 alpha inhibitor 1
BelzutifanPhase 2
Registry, Nov 18, 2032
HSP90 inhibitor (with imatinib) 1
Pimitespib + ImatinibPhase 1
Registry, Dec 2026
KIT type I TKI plus type II TKI combination 1
No dated milestone in 2025 to 2030
KIT-directed ADC 1
Registry, Aug 30, 2027
KIT/PDGFRA TKI (type II) 1
ImatinibApproved
No dated milestone in 2025 to 2030
KIT/PDGFRA type I TKI 1
AvapritinibApproved
No dated milestone in 2025 to 2030
menin inhibitor (with imatinib) 1
Ziftomenib + ImatinibPhase 1
Registry, Jun 2029
multi-kinase TKI 2
RegorafenibApproved
No dated milestone in 2025 to 2030
Olverembatinib (HQP1351)Phase 3
Registry, Mar 31, 2027
multi-kinase TKI (type II) 1
SunitinibApproved
No dated milestone in 2025 to 2030
selective KIT TKI 2
Registry, Mar 10, 2027
NB003Phase 2/3
Registry, Aug 2028
switch-control KIT/PDGFRA TKI 1
RipretinibApproved
Registry, Dec 2027
VEGFR2 TKI (with paclitaxel) 1
Rivoceranib + PaclitaxelPhase 2
Registry, Aug 31, 2027